Newsroom | 26461 results

BONITA SPRINGS, Fla.--(BUSINESS WIRE)--Optivate, a leading provider of specialty-built software and solutions for ophthalmology practices, today announced the appointment of Brad Caldwell as Chief Executive Officer. Abdiel Marin, the company’s Founder and CEO, will transition to a role as an advisor and remain on the Board of Directors as the company enters its next phase of growth. Caldwell brings extensive experience in healthcare technology, go-to-market strategy, and operational leadership....

BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at Jefferies Global Healthcare Conference on Thursday, June 4, 2026, in New York, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive...

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, leider in AI-gestuurde ziekteopsporing en intelligente zorgcoördinatie, heeft vandaag de lancering aangekondigd van de Viz Pulmonary™ Suite, een geïntegreerde AI-oplossing binnen het Viz.ai-bedrijfsplatform. Deze suite is ontworpen om zorgsystemen te helpen de zorgverlening voor longaandoeningen te stroomlijnen. De suite brengt acute en chronische longworkflows samen in één oplossing, waardoor clinici patiënten efficiënter kunnen behandelen en hen de volg...

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, leader en matière de détection des maladies par intelligence artificielle et de coordination intelligente des soins, annonce aujourd'hui le lancement de sa suite Viz Pulmonary™, une solution intégrée alimentée par l'IA et intégrée à sa plateforme d'entreprise. Cette solution vise à simplifier la prise en charge des affections pulmonaires au sein des établissements de santé. Elle centralise les workflows liés aux pathologies pulmonaires aiguës et chronique...

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, der Marktführer im Bereich der KI-gestützten Erkennung von Erkrankungen und der intelligenten Versorgungskoordination, gab heute die Einführung der Viz Pulmonary™ Suite bekannt, einer integrierten, KI-gestützten Lösung innerhalb der Viz.ai-Unternehmensplattform, die Gesundheitssystemen dabei helfen soll, die Versorgung bei Lungenerkrankungen zu optimieren. Die Suite vereint Arbeitsabläufe für akute und chronische Lungenerkrankungen in einer einzigen Lösun...

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, líder en detección de enfermedades con IA y coordinación inteligente de la atención médica, ha anunciado hoy el lanzamiento de Viz Pulmonary™ Suite, una solución con IA integrada en la plataforma empresarial de Viz.ai. Esta solución fue diseñada para ayudar a los sistemas sanitarios a optimizar la prestación de la atención en las afecciones pulmonares. Además reúne los flujos de trabajo relacionados con las afecciones pulmonares agudas y crónicas en una ú...

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, il leader nel rilevamento delle malattie basato sull'intelligenza artificiale e nel coordinamento intelligente delle cure, oggi ha annunciato il lancio di Viz Pulmonary™ Suite, una soluzione integrata basata sull'intelligenza artificiale all'interno della piattaforma aziendale Viz.ai, progettata per aiutare i sistemi sanitari a semplificare l'assistenza ai pazienti con patologie polmonari. La suite riunisce flussi di lavoro relativi a patologie polmonari...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer...

NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (“QT Imaging” or the “Company”) (Nasdaq: QTI), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, announced today the pricing of an underwritten public offering of 2,000,000 shares of common stock (or pre-funded warrants in lieu thereof) for gross proceeds of $10 million. Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager and Northland...

PALO ALTO, Calif.--(BUSINESS WIRE)--Valar Labs, an AI precision oncology company developing diagnostics that predict cancer treatment response from routine pathology slides, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Vesta Bladder Risk Stratify Dx. With this designation, Vesta Bladder Risk Stratify Dx becomes the first AI-powered digital pathology prognostic test in bladder cancer to receive FDA Breakthrough status, marking a...